![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF (STB) has Durable Efficacy and Differentiated Long-Term Safety and Tolerability Versus Efavirenz/Emtricitabine/Tenofovir DF (ATR) at Week 144 in Treatment-Naïve HIV Patients
|
|
|
Reported by Jules Levin
53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) September 10-13, 2013Denver, CO, USA
D Wohl1, C Cohen2, JE Gallant3, A Mills4, P Sax5, E DeJesus6, A Zolopa7, HC Liu8, K White8, MS Rhee8, J Szwarcberg8
1University of North Carolina, Chapel Hill, NC, US; 2Community Research Initiative of New England, Boston, MA, US; 3Southwest CARE Center, Santa Fe, NM, US; 4Anthony Mills MD, Inc., Los Angeles, CA, US; 5Brigham and Women's Hospital, Harvard Medical School, Boston, MA, US; 6Orlando Immunology Center, Orlando, FL, US; 7Stanford University, Palo Alto, CA, US; 8Gilead Sciences, Foster City, CA, US
![ICAAC1.gif](../images/091613/091613-10/ICAAC1.gif)
![ICAAC2.gif](../images/091613/091613-10/ICAAC2.gif)
![ICAAC3.gif](../images/091613/091613-10/ICAAC3.gif)
![ICAAC4.gif](../images/091613/091613-10/ICAAC4.gif)
![ICAAC5.gif](../images/091613/091613-10/ICAAC5.gif)
![ICAAC6.gif](../images/091613/091613-10/ICAAC6.gif)
![ICAAC7.gif](../images/091613/091613-10/ICAAC7.gif)
![ICAAC8.gif](../images/091613/091613-10/ICAAC8.gif)
![ICAAC9.gif](../images/091613/091613-10/ICAAC9.gif)
![ICAAC10.gif](../images/091613/091613-10/ICAAC10.gif)
![ICAAC11.gif](../images/091613/091613-10/ICAAC11.gif)
![ICAAC12.gif](../images/091613/091613-10/ICAAC12.gif)
![ICAAC13.gif](../images/091613/091613-10/ICAAC13.gif)
![ICAAC14.gif](../images/091613/091613-10/ICAAC14.gif)
![ICAAC15.gif](../images/091613/091613-10/ICAAC15.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|